High‐risk cytogenetic abnormalities in multiple myeloma: PETHEMA‐GEM experience
Abstract This study examines the impact of cytogenetic abnormalities and their co‐segregation on the prognosis of newly diagnosed multiple myeloma patients. The analysis included 1304 patients from four different GEM‐PETHEMA clinical trials. Genetic alterations, such as t(4;14), t(14;16), del(17p),...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | HemaSphere |
| Online Access: | https://doi.org/10.1002/hem3.70031 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841556213772320768 |
|---|---|
| author | Veronica González‐Calle Paula Rodriguez‐Otero Maria J. Calasanz Manuela Guijarro Joaquin Martínez‐López Laura Rosiñol Miguel T. Hernández Ana I. Teruel Mercedes Gironella Albert Oriol Javier de laRubia Ana P. González‐Rodríguez Joan Bargay Felipe deArriba Luis Palomera Marta‐Sonia González‐Pérez Anna Sureda Enrique Ocio Juan J. Lahuerta Joan Bladé Jesus F. San Miguel Maria V. Mateos Norma C. Gutiérrez |
| author_facet | Veronica González‐Calle Paula Rodriguez‐Otero Maria J. Calasanz Manuela Guijarro Joaquin Martínez‐López Laura Rosiñol Miguel T. Hernández Ana I. Teruel Mercedes Gironella Albert Oriol Javier de laRubia Ana P. González‐Rodríguez Joan Bargay Felipe deArriba Luis Palomera Marta‐Sonia González‐Pérez Anna Sureda Enrique Ocio Juan J. Lahuerta Joan Bladé Jesus F. San Miguel Maria V. Mateos Norma C. Gutiérrez |
| author_sort | Veronica González‐Calle |
| collection | DOAJ |
| description | Abstract This study examines the impact of cytogenetic abnormalities and their co‐segregation on the prognosis of newly diagnosed multiple myeloma patients. The analysis included 1304 patients from four different GEM‐PETHEMA clinical trials. Genetic alterations, such as t(4;14), t(14;16), del(17p), +1q, and del(1p), were investigated using FISH on CD38 purified plasma cells. The frequency of genetic alterations detected were as follows: del(17p) in 8%, t(4;14) in 12%, t(14;16) in 3%, +1q in 43%, and del(1p) in 8%. The median follow‐up was 61 months, and the median progression‐free survival (PFS) and overall survival (OS) were 44 months and not reached, respectively. Consistent with previous reports, the presence of t(4;14) was associated with shorter PFS and OS. In our series, the presence of t(14;16) did not impact survival, maybe due to limitations in sample size. Del(17p) was linked to poor prognosis using a cut‐off level of ≥20% positive cells, without any impact of higher cut‐off in prognosis, except for patients with clonal fraction ≥80% who had a dismal outcome. Cosegregation of cytogenetic abnormalities patients worsened the prognosis in t(4;14) patients but not in patients with del(17p), which retained its adverse prognosis even as a solitary abnormality. Gain(1q) was associated with significantly shorter PFS and OS, while del(1p) affected PFS but not OS. Nevertheless, when co‐segregation was eliminated, the detrimental effect of +1q or del(1p) was no longer observed. In conclusion, this study confirms the prognostic significance of high‐risk cytogenetic abnormalities in MM and highlights the importance of considering co‐occurrence for accurate prognosis assessment. |
| format | Article |
| id | doaj-art-21080f16bf9d464d928866b682d9fa90 |
| institution | Kabale University |
| issn | 2572-9241 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj-art-21080f16bf9d464d928866b682d9fa902025-01-07T12:35:28ZengWileyHemaSphere2572-92412024-12-01812n/an/a10.1002/hem3.70031High‐risk cytogenetic abnormalities in multiple myeloma: PETHEMA‐GEM experienceVeronica González‐Calle0Paula Rodriguez‐Otero1Maria J. Calasanz2Manuela Guijarro3Joaquin Martínez‐López4Laura Rosiñol5Miguel T. Hernández6Ana I. Teruel7Mercedes Gironella8Albert Oriol9Javier de laRubia10Ana P. González‐Rodríguez11Joan Bargay12Felipe deArriba13Luis Palomera14Marta‐Sonia González‐Pérez15Anna Sureda16Enrique Ocio17Juan J. Lahuerta18Joan Bladé19Jesus F. San Miguel20Maria V. Mateos21Norma C. Gutiérrez22Department of Hematology, Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC‐USAL, CSIC) CIBERONC Salamanca SpainDepartment of Hematology, Cancer Center Clinica Universidad de Navarra, CCUN, Centro de Investigacion Medica Aplicadas (Cima); Instituto de Investigación Sanitaria de Navarra (IDISNA) CIBERONC Pamplona SpainDepartment of Hematology, Cancer Center Clinica Universidad de Navarra, CCUN, Centro de Investigacion Medica Aplicadas (Cima); Instituto de Investigación Sanitaria de Navarra (IDISNA) CIBERONC Pamplona SpainDepartment of Hematology, Hospital Universitario 12 de Octubre, I + 12, CNIO Complutense University, CIBERONC Madrid SpainDepartment of Hematology, Hospital Universitario 12 de Octubre, I + 12, CNIO Complutense University, CIBERONC Madrid SpainDepartment of Hematology, Hospital Clínic IDIBAPS Barcelona SpainDepartment of Hematology Hospital Universitario de Canarias Tenerife SpainDepartment of Hematology Hospital Clínico de Valencia Valencia SpainDepartment of Hematology Hospital Vall d'Hebron Barcelona SpainDepartment of Hematology, Institut Català d'Oncologia i Institut Josep Carreras Hospital Germans Trias i Pujol Badalona SpainDepartment of Hematology, Hospital Universitario y Politécnico La Fe CIBERONC Valencia SpainDepartment of Hematology Hospital Universitario Central De Asturias Oviedo SpainDepartment of Hematology Hospital Son Llatzer Palma de Mallorca SpainDepartment of Hematology, Hospital Morales Meseguer, IMIB‐Pascual Parrilla Universidad de Murcia Murcia SpainDepartment of Hematology Hospital Clinico Universitario Lozano Blesa Zaragoza SpainDepartment of Hematology, University Hospital of Santiago de Compostela Servizo Galego de Saúde (SERGAS) Santiago de Compostela SpainDepartment of Hematology Institut Català D'Oncologia L'Hospitalet Badalona SpainDepartment of Hematology Hospital Universitario Marques de Valdecilla Santander SpainDepartment of Hematology, Hospital Universitario 12 de Octubre, I + 12, CNIO Complutense University, CIBERONC Madrid SpainDepartment of Hematology, Hospital Clínic IDIBAPS Barcelona SpainDepartment of Hematology, Cancer Center Clinica Universidad de Navarra, CCUN, Centro de Investigacion Medica Aplicadas (Cima); Instituto de Investigación Sanitaria de Navarra (IDISNA) CIBERONC Pamplona SpainDepartment of Hematology, Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC‐USAL, CSIC) CIBERONC Salamanca SpainDepartment of Hematology, Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC‐USAL, CSIC) CIBERONC Salamanca SpainAbstract This study examines the impact of cytogenetic abnormalities and their co‐segregation on the prognosis of newly diagnosed multiple myeloma patients. The analysis included 1304 patients from four different GEM‐PETHEMA clinical trials. Genetic alterations, such as t(4;14), t(14;16), del(17p), +1q, and del(1p), were investigated using FISH on CD38 purified plasma cells. The frequency of genetic alterations detected were as follows: del(17p) in 8%, t(4;14) in 12%, t(14;16) in 3%, +1q in 43%, and del(1p) in 8%. The median follow‐up was 61 months, and the median progression‐free survival (PFS) and overall survival (OS) were 44 months and not reached, respectively. Consistent with previous reports, the presence of t(4;14) was associated with shorter PFS and OS. In our series, the presence of t(14;16) did not impact survival, maybe due to limitations in sample size. Del(17p) was linked to poor prognosis using a cut‐off level of ≥20% positive cells, without any impact of higher cut‐off in prognosis, except for patients with clonal fraction ≥80% who had a dismal outcome. Cosegregation of cytogenetic abnormalities patients worsened the prognosis in t(4;14) patients but not in patients with del(17p), which retained its adverse prognosis even as a solitary abnormality. Gain(1q) was associated with significantly shorter PFS and OS, while del(1p) affected PFS but not OS. Nevertheless, when co‐segregation was eliminated, the detrimental effect of +1q or del(1p) was no longer observed. In conclusion, this study confirms the prognostic significance of high‐risk cytogenetic abnormalities in MM and highlights the importance of considering co‐occurrence for accurate prognosis assessment.https://doi.org/10.1002/hem3.70031 |
| spellingShingle | Veronica González‐Calle Paula Rodriguez‐Otero Maria J. Calasanz Manuela Guijarro Joaquin Martínez‐López Laura Rosiñol Miguel T. Hernández Ana I. Teruel Mercedes Gironella Albert Oriol Javier de laRubia Ana P. González‐Rodríguez Joan Bargay Felipe deArriba Luis Palomera Marta‐Sonia González‐Pérez Anna Sureda Enrique Ocio Juan J. Lahuerta Joan Bladé Jesus F. San Miguel Maria V. Mateos Norma C. Gutiérrez High‐risk cytogenetic abnormalities in multiple myeloma: PETHEMA‐GEM experience HemaSphere |
| title | High‐risk cytogenetic abnormalities in multiple myeloma: PETHEMA‐GEM experience |
| title_full | High‐risk cytogenetic abnormalities in multiple myeloma: PETHEMA‐GEM experience |
| title_fullStr | High‐risk cytogenetic abnormalities in multiple myeloma: PETHEMA‐GEM experience |
| title_full_unstemmed | High‐risk cytogenetic abnormalities in multiple myeloma: PETHEMA‐GEM experience |
| title_short | High‐risk cytogenetic abnormalities in multiple myeloma: PETHEMA‐GEM experience |
| title_sort | high risk cytogenetic abnormalities in multiple myeloma pethema gem experience |
| url | https://doi.org/10.1002/hem3.70031 |
| work_keys_str_mv | AT veronicagonzalezcalle highriskcytogeneticabnormalitiesinmultiplemyelomapethemagemexperience AT paularodriguezotero highriskcytogeneticabnormalitiesinmultiplemyelomapethemagemexperience AT mariajcalasanz highriskcytogeneticabnormalitiesinmultiplemyelomapethemagemexperience AT manuelaguijarro highriskcytogeneticabnormalitiesinmultiplemyelomapethemagemexperience AT joaquinmartinezlopez highriskcytogeneticabnormalitiesinmultiplemyelomapethemagemexperience AT laurarosinol highriskcytogeneticabnormalitiesinmultiplemyelomapethemagemexperience AT miguelthernandez highriskcytogeneticabnormalitiesinmultiplemyelomapethemagemexperience AT anaiteruel highriskcytogeneticabnormalitiesinmultiplemyelomapethemagemexperience AT mercedesgironella highriskcytogeneticabnormalitiesinmultiplemyelomapethemagemexperience AT albertoriol highriskcytogeneticabnormalitiesinmultiplemyelomapethemagemexperience AT javierdelarubia highriskcytogeneticabnormalitiesinmultiplemyelomapethemagemexperience AT anapgonzalezrodriguez highriskcytogeneticabnormalitiesinmultiplemyelomapethemagemexperience AT joanbargay highriskcytogeneticabnormalitiesinmultiplemyelomapethemagemexperience AT felipedearriba highriskcytogeneticabnormalitiesinmultiplemyelomapethemagemexperience AT luispalomera highriskcytogeneticabnormalitiesinmultiplemyelomapethemagemexperience AT martasoniagonzalezperez highriskcytogeneticabnormalitiesinmultiplemyelomapethemagemexperience AT annasureda highriskcytogeneticabnormalitiesinmultiplemyelomapethemagemexperience AT enriqueocio highriskcytogeneticabnormalitiesinmultiplemyelomapethemagemexperience AT juanjlahuerta highriskcytogeneticabnormalitiesinmultiplemyelomapethemagemexperience AT joanblade highriskcytogeneticabnormalitiesinmultiplemyelomapethemagemexperience AT jesusfsanmiguel highriskcytogeneticabnormalitiesinmultiplemyelomapethemagemexperience AT mariavmateos highriskcytogeneticabnormalitiesinmultiplemyelomapethemagemexperience AT normacgutierrez highriskcytogeneticabnormalitiesinmultiplemyelomapethemagemexperience |